Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucin-degrading metalloprotease YghJ, also known as SslE, is a large secreted lipoprotein and a critical virulence factor found in various pathogenic Escherichia coli strains, including Enterotoxigenic E. coli (ETEC) and Extraintestinal Pathogenic E. coli (ExPEC) (Luo et al., 2014, PMID: 24818661). It functions as a zinc-metalloprotease belonging to the M60-like family, specifically targeting and degrading host mucin glycoproteins (such as MUC2 and MUC3) that constitute the protective mucus barrier of the intestinal and extraintestinal tracts (Nesta et al., 2014, PMID: 24639449). By breaking down this barrier, YghJ facilitates bacterial penetration and subsequent adhesion to the underlying epithelial cells, which is essential for colonization and the delivery of toxins (Luo et al., 2014, PMID: 24818661). The protein undergoes O-linked glycosylation, a post-translational modification that may influence its stability and role as a surface-exposed antigen (UniProt, P0CK95). Due to its high conservation across diverse E. coli pathotypes and its indispensable role in infection, YghJ is a primary target for the development of broadly protective vaccines and therapeutic antibodies (Nesta et al., 2014, PMID: 24639449). Experimental studies have demonstrated that antibodies targeting YghJ can effectively neutralize its mucinase activity and reduce bacterial load in vivo (Fleckenstein et al., 2014, PMID: 24933307).
Neutralization of the protease activity to prevent the degradation of the host's protective mucus layer, thereby inhibiting bacterial access and adhesion to the underlying epithelial cells (Nesta et al., 2014, PMID: 24639449).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin-degrading metalloprotease YghJ (YghJ).